News

Olaparib Phase 3 Development Discontinued by AstraZeneca

(January 1, 2012) In a surprise announcement, AstraZeneca put out a press release in late December announcing the cancellation Phase 3 development for olaparib. The official reason given for abandoning development was as follows: “The decision to discontinue olaparib’s development in serous ovarian cancer was made following a review of an interim analysis of a …

Olaparib Phase 3 Development Discontinued by AstraZenecaRead More »

Clovis to Develop Pfizer’s PARP Inhibitor

Clovis Oncology will develop Pfizer’s PF-01367338 PARP Inhibitor under a development and licensing agreement announced today worth $255 million. Pfizer’s oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, PF-01367338 is currently  in Phase 1/2 development for solid tumors. PF-01367338 is a novel, orally active, small molecule inhibitor of PARP and will be developed by Clovis …

Clovis to Develop Pfizer’s PARP InhibitorRead More »